| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-09-09 | Adaptimmune (UK) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-09-08 | Pierre Fabre (France) Addex Therapeutics (Switzerland) | mGlu3 receptor program | CNS diseases | licensing |
CNS diseases | Licensing agreement |
| 2015-09-08 | Cytori Therapeutics (USA - CA) | nomination |
Nomination | |||
| 2015-09-08 | Purdue Pharma (USA - CT) VM Pharma (USA - CA) | VM-902A and TrkA Program | pain | product acquisition |
CNS diseases - Neurological diseases | Pipeline acquisition |
| 2015-09-08 | AstraZeneca (UK) the University of Manchester (UK) | clinical trial bioinformatics | collaboration |
Cancer - Oncology - Technology - Services | Collaboration agreement | |
| 2015-09-08 | Kancera (Sweden) Acturum Life Science (Sweden) | AZD8797 - Fractalkine project | R&D development |
Cancer - Oncology | Development agreement | |
| 2015-09-08 | Debiopharm (Switzerland) Solid Biosciences (USA - MA) | alisporivir (DEB025) | Duchenne muscular dystrophy (DMD) | collaboration |
Rare diseases - Genetic diseases - Neuromuscular diseases | Collaboration agreement |
| 2015-09-08 | Immune Pharmaceuticals (USA - MA, Israel) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-09-08 | Sobi - Swedish Orphan Biovitrum (Sweden) | European and Benelux office in Brussels | opening of new premises | Rare diseases - Genetic diseases | Opening of new premises | |
| 2015-09-08 | Threshold Pharmaceuticals (USA - CA) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-09-07 | Eisai (Japan) Purdue Pharma (USA - CT) | lemborexant | insomnia | development commercialisation |
CNS diseases | Development agreement |
| 2015-09-07 | BMS (USA - NY) Promedior (USA - MA) | PRM-151 (recombinant human pentraxin-2) | idiopathic pulmonary fibrosis (IPF), myelofibrosis (MF), fibrotic diseases | product acquisition |
Rare diseases - Fibrotic diseases | Product acquisition |
| 2015-09-07 | AstraZeneca (UK) Starpharma (Australia) | DEP® drug delivery platform | licensing |
Cancer - Oncology - Technology - Services | Licensing agreement | |
| 2015-09-07 | Novo Nordisk (Denmark) Massachusetts Institute of Technology (USA - MA) | drug delivery devices for oral delivery of peptides | R&D |
R&D agreement | ||
| 2015-09-07 | Merck Serono, a Merck KGaA company (Germany) Relief Therapeutics (Switzerland) | atexakin alfa | neuropathies including diabetic neuropathy | licensing |
Neurological diseases - Metabolic diseases | Licensing agreement |
| 2015-09-04 | Cortendo (Sweden) Strongbridge Biopharma (Ireland) | relocation of the parent company |
Rare diseases | Establishment of a new subsidiary in the EU | ||
| 2015-09-04 | Celyad (Belgium) | nomination |
Cardiovascular diseases - Regenerative medicine | Nomination | ||
| 2015-09-03 | Horizon Discovery (UK) Redx Pharma (UK) | pan-RAF inhibitor program | R&D |
Cancer - Oncology | R&D agreement | |
| 2015-09-03 | Cellectis (France) The University of Texas MD Anderson Cancer Center (USA - TX) | cellular immunotherapies | liquid tumors | R&D |
Cancer - Oncology | R&D agreement |
| 2015-09-03 | Acadia Pharmaceuticals (USA - CA) | nomination |
CNS diseases - Neurological diseases - Neurodegenerative diseases | Nomination |
